Abstract Number: 276 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcome in Mixed Connective Tissue Disease
Background/Purpose: The question of whether mixed connective tissue disease (MCTD) is a distinct entity still remains controversial. For this reason, we have investigated the long-term…Abstract Number: 277 • 2015 ACR/ARHP Annual Meeting
Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study
Background/Purpose: To investigate the safety and preliminary efficacy of rituximab (RTX) in patients with refractory mixed connective tissue disease (MCTD) Methods: We evaluated 9 patients in…Abstract Number: 278 • 2015 ACR/ARHP Annual Meeting
Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome
Background/Purpose: Joint Hypermobility Syndrome (JHS) may predispose to ligamentous rupture, joint dislocations, fibromyalgia, premature osteoarthritis and non-articular complications include Mitral Valve Prolapse (MVP) (Barron J…Abstract Number: 279 • 2015 ACR/ARHP Annual Meeting
Ehlers-Danlos Syndrome Hypermobility Type (Type III) Is Associated with Rheumatological Conditions
Background/Purpose: Ehlers-Danlos syndrome is a group of inherited conditions caused by genetic mutations in collagen genes, such as COL5A, COL3A, etc, resulting in defects in…Abstract Number: 280 • 2015 ACR/ARHP Annual Meeting
The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
Background/Purpose: We previously reported that inflammation occurred early in the fascia of patients with dermatomyositis. We often encounter patients with autoimmune diseases who present with…Abstract Number: 281 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Reduced in Adult Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM), such as dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM), are chronic multi-systemic inflammatory conditions. Substantial studies on health…Abstract Number: 282 • 2015 ACR/ARHP Annual Meeting
Angiogenesis in Fasciitis Associated with Dermatomyositis
Background/Purpose: We have previously demonstrated that fasciitis is a common lesion of dermatomyositis (DM) detectable early after disease onset. Furthermore, en bloc biopsy showed that the…Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…Abstract Number: 284 • 2015 ACR/ARHP Annual Meeting
Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment
Background/Purpose: Patient-reported outcomes (PROs) assess disease symptoms and impact from the patient’s perspective. This research aimed to establish the validity, reliability, and responsiveness of the…Abstract Number: 285 • 2015 ACR/ARHP Annual Meeting
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Background/Purpose: Smoking has been found to be a risk or protective factor in certain autoimmune diseases. Yet, its role in the idiopathic inflammatory myopathies (IIM)…Abstract Number: 287 • 2015 ACR/ARHP Annual Meeting
Interleukin-35 in Idiopathic Inflammatory Myopathies
Background/Purpose: Interleukin-35 (IL-35) is a newly described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. IL-35…Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…Abstract Number: 289 • 2015 ACR/ARHP Annual Meeting
Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
Background/Purpose: Because of the extremely variable incidence and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM), explorationand validation of biomarkers for diagnosis, prognosis, and response…Abstract Number: 290 • 2015 ACR/ARHP Annual Meeting
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Background/Purpose: Twenty percent of inflammatory myopathy are associated with a synchronous cancer occurring ±3 years around the diagnosis. Malignancy is a major cause of mortality…Abstract Number: 291 • 2015 ACR/ARHP Annual Meeting
Correlations Between Muscle-MRI, Muscle Strength and Creatine Kinase Levels in the Anti-Synthetase Syndrome; A Comparative, Cross-Sectional Study
Background/Purpose: Muscle MRI is used to describe the myositis component of the anti-synthetase syndrome (ASS), but the value of the examination is limited by lack…
ACR Meeting Abstracts